Practical Theoretical Course at the LXY Institute in MADRID!
The theoretical – practical course at the LXY Institute in Madrid, where EchoLaser TPLA played a central role as a treatment for IPB, ended.
Discover more thanks to Dr. Pablo Garrido Abad!
III Edición Curso Práctico en STUI y Patología Vesicoprostática basado en Simulación
EchoLaser: the first choice
The echolaser phenomenon for the treatment of benign prostatic hyperplasia is spreading without limits. TPLA is increasingly being used among professionals with enormous satisfaction.
Is the turn of the hospital paolo borsellino of Marsala with Dr. Emanuele Caldarera and his team!
a great wish to the structure for an excellent journey together aimed at patient care
Wonderful Donations In UK
We are thrilled to announce the successful delivery of an EchoLaser TPLA to The Royal Surrey County Hospital, made possible by the generous donation from The Prostate Project. This cutting-edge medical equipment will provide new treatment options for patients suffering from benign prostatic hyperplasia (BPH) within the NHS system.
This achievement marks a significant step forward in advancing medical technology in the UK, and we look forward to the positive impact it will have on patients’ lives.
Learn more about our mission to improve patient outcomes and advance healthcare innovation at www.elesta-echolaser.com.
https://www.royalsurrey.nhs.uk/news/echo-laser-machine-to-treat-prostate-enlargement-10388
First Time Worldwide Use of Radio-Opaque Markers in Focal Treatment for the Prostate Cancer
EchoLaser is a multichannel laser system used for the ultrasound or fusionguided laser ablation of both benign and malignant lesions in the prostate, such as Benign Prostatic Hyperplasia and localized Prostate Cancer. EchoLaser was developed by the Italian Med-Tech company Elesta.
The EchoLaser procedure is micro-invasive. The laser works employing laser light transmitted by extremely fine (less than 1 mm in diameter) applicators with transperineal access, to heat the targeted lesion causing irreversible “in situ” damage without the need of tissue removal. The procedure is supported by the Echolaser Smart Interface (ESI), a dedicated software that helps the physician to correctly position of the optic fibers, raising the bar of safety and precision.
The treatment is performed in an outpatient setting under local anaesthesia in 20 to 40 minutes. The EchoLaser technology allows the preservation of the organ and its functionality. Minor risks are associated to the EchoLaser, avoiding trauma and complications related to the surgical approach. The patient comes back to daily activities just few hours after the treatment. Reduced operation time and absence of hospitalization allowing a fast patient management are additional fundamental features.
EchoLaser micro-invasive procedures have been performed for several years in Italian and International Centres of Excellence, generating a robust and growing clinical evidence.
EchoLaser treatment for the focal therapy of prostate cancer is available in Greece at Athens Medical Center Psychico Clinic with Dr. Brembos and his team. Here Dr. Brembos, for the first time worldwide, started treating prostate cancers with EchoLaser technology in combination with radiopaque gold marker (clearly visible on MRI and transrectal US) that, combined with ESI, improves the effectiveness of the lesion targeting. The markers positioned during biopsy procedure provide a tool to aim better the prostate cancer position, localize the tumour in a more accurate way and reduce the treatment time in the planning phase. Patients were treated in 30 minutes, without complications and in outpatient setting.
